ALK inhibitor

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

ALK inhibitor

Jan 13, 2025, 15:46 | Science

Vivek Subbiah: Interesting commentary on Weight gain and ALK inhibitors by Cathleen June Park, et al.

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared…

Dec 21, 2024, 08:48 | Science

Oncology Brothers: Another ALK inhibitor gets FDA approval

Oncology Brothers posted on X: "Another ALK inhibitor (ensartinib) gets FDA approval eXalt3 study: 1L,…

Sep 14, 2024, 17:45 | Insight

Jacob Adashek: Can Gilteritinib achieve a complete morphologic response in ALK-rearranged acute myeloid leukemia?

Jacob J. Adashek shared a post on LinkedIn: "HOT OFF THE PRESS in Nature Portfolio with…

May 1, 2024, 12:57 | Blog

Chris Boshoff: Pfizer in ASCO24

Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared a post on LinkedIn:…

All: 4 Posts: 1 - 100

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

'

King Charles III Hospitalized Following Side Effects from Cancer Treatment

'

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

'

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023